ENGLEWOOD, Colo., Feb. 17,
2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an
innovative medical technology company specializing in the
manufacture and sale of non-invasive medical devices for pain
management, rehabilitation, and patient monitoring, today
announced that it is set to join the MSCI USA Small Cap Index according to the list of
additions posted by MSCI on February 9,
2023. Inclusion in the index will take effect after the
market close on February 28,
2023.
"We are delighted for Zynex to be included in the MSCI
USA Small Cap Index as it marks
another significant capital markets milestone," said Thomas Sandgaard, CEO and Founder of Zynex. "The
inclusion will generate a broader awareness and enhance visibility
of Zynex among the investor community as we continue our mission to
improve the quality of life for patients suffering from
debilitating pain or illness."
The MSCI USA Small Cap Index is
designed to measure the performance of the small cap segment of the
U.S. equity market. With 1,935 constituents, the index represents
approximately 14% of the free float-adjusted market capitalization
in the U.S. MSCI indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. For more information on the MSCI
Index, please visit https://www.msci.com/our-solutions/indexes.
About Zynex, Inc.
Zynex, founded in
1996, develops, manufactures, markets, and sells medical devices
used for pain management and rehabilitation as well as non-invasive
fluid, sepsis, and laser-based pulse oximetry
monitoring systems for use in hospitals. For additional
information, please
visit: www.zynex.com.
Safe Harbor Statement
This release contains
forward-looking statements within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results and financial
condition may differ materially from those indicated in the
forward-looking statements. Therefore you should not rely on any of
these forward looking statements. The Company makes no express or
implied representation or warranty as to the completeness of
forward-looking statements or, in the case of projections, as to
their attainability or the accuracy and completeness of the
assumptions from which they are derived. Factors that could cause
actual results to materially differ from forward-looking statements
include, but are not limited to, the need to obtain C.E. marking of
new products, the acceptance of new products as well as existing
products by doctors and hospitals, larger competitors with greater
financial resources, the need to keep pace with technological
changes, our dependence on the reimbursement for our products from
health insurance companies, our dependence on third party
manufacturers to produce our products on time and to our
specifications, implementation of our sales strategy including a
strong direct sales force, the impact of COVID-19 on the global
economy and other risks described in our filings with the
Securities and Exchange Commission including but not limited to,
our Annual Report on Form 10-K for the year ended December 31, 2021 as well as our quarterly
reports on Form 10-Q and current reports on Form 8-K.
Any forward-looking statement made by us in this release is
based only on information currently available to us and speaks only
as of the date on which it is made. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
Contact: Zynex, Inc. (800) 495-6670
Investor
Relations Contact:
Gilmartin Group
Investor Relations Counsel
ir@zynex.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/zynex-announces-inclusion-in-msci-usa-small-cap-index-301749845.html
SOURCE Zynex